NO945103L - Ribozym med en termodynamisk stabil lökke - Google Patents

Ribozym med en termodynamisk stabil lökke

Info

Publication number
NO945103L
NO945103L NO945103A NO945103A NO945103L NO 945103 L NO945103 L NO 945103L NO 945103 A NO945103 A NO 945103A NO 945103 A NO945103 A NO 945103A NO 945103 L NO945103 L NO 945103L
Authority
NO
Norway
Prior art keywords
ribozyme
polyribonucleotide
thermodynamically stable
stable loop
forth
Prior art date
Application number
NO945103A
Other languages
English (en)
Other versions
NO945103D0 (no
NO311258B1 (no
Inventor
Eiko Otsuka
Makoto Koizumi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO945103D0 publication Critical patent/NO945103D0/no
Publication of NO945103L publication Critical patent/NO945103L/no
Publication of NO311258B1 publication Critical patent/NO311258B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122Hairpin

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19945103A 1992-07-02 1994-12-30 Ribozym for in-vitro spalting av polyribonukleotid med en termodynamisk stabil lökke NO311258B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP17570692 1992-07-02
JP23691692 1992-09-04
PCT/JP1993/000907 WO1994001549A1 (fr) 1992-07-02 1993-07-02 Ribozyme bouclee en epingle a cheveux

Publications (3)

Publication Number Publication Date
NO945103D0 NO945103D0 (no) 1994-12-30
NO945103L true NO945103L (no) 1995-03-02
NO311258B1 NO311258B1 (no) 2001-11-05

Family

ID=26496887

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19945103A NO311258B1 (no) 1992-07-02 1994-12-30 Ribozym for in-vitro spalting av polyribonukleotid med en termodynamisk stabil lökke

Country Status (8)

Country Link
US (1) US5631115A (no)
EP (1) EP0653488B1 (no)
AT (1) ATE236975T1 (no)
AU (1) AU672018B2 (no)
CA (1) CA2139411A1 (no)
DE (1) DE69332856D1 (no)
NO (1) NO311258B1 (no)
WO (1) WO1994001549A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19532651A1 (de) * 1995-09-05 1997-03-06 Aloysius Dr Dickgreber Mittel zur therapeutischen Anwendung bei HIV-Infektionen
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US6274369B1 (en) * 1996-02-02 2001-08-14 Invitrogen Corporation Method capable of increasing competency of bacterial cell transformation
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (en) 2000-10-12 2003-07-16 University of Rochester Compositions that inhibit proliferation of cancer cells
MXPA04007586A (es) 2002-02-06 2005-06-08 Vicor Technologies Inc Moleculas anti-infarto.
EP1534729A2 (en) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
CA2507863A1 (en) * 2002-12-04 2004-06-17 Algos Therapeutics, Inc. Methods and materials for modulating trpm2
US8129124B2 (en) 2005-02-02 2012-03-06 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
EP1934244A2 (en) * 2005-10-06 2008-06-25 Emthrax LLC Methods and compositions relating to anthrax spore glycoproteins as vaccines
US8093369B2 (en) * 2005-10-11 2012-01-10 Ben Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of VDAC1 and uses thereof
EP2392647A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20100190689A1 (en) 2006-09-21 2010-07-29 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
DE602007014389D1 (de) * 2006-11-01 2011-06-16 Medical Res And Infrastructure Fund Of The Tel Aviv Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
CN101600451A (zh) 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP2986317A4 (en) 2013-04-15 2016-10-05 Yeda Res & Dev INHIBITION OF RIP KINASES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
AU2017306422A1 (en) 2016-08-03 2019-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
US12492245B2 (en) 2021-09-21 2025-12-09 University Of South Carolina Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005852A1 (en) * 1987-12-15 1989-06-29 Macphillamy Cummins & Gibson Ribozymes
CA1340323C (en) * 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences

Also Published As

Publication number Publication date
AU672018B2 (en) 1996-09-19
EP0653488A1 (en) 1995-05-17
EP0653488B1 (en) 2003-04-09
ATE236975T1 (de) 2003-04-15
DE69332856D1 (de) 2003-05-15
CA2139411A1 (en) 1994-01-20
EP0653488A4 (en) 1997-01-15
WO1994001549A1 (fr) 1994-01-20
AU4513093A (en) 1994-01-31
US5631115A (en) 1997-05-20
NO945103D0 (no) 1994-12-30
NO311258B1 (no) 2001-11-05

Similar Documents

Publication Publication Date Title
NO945103L (no) Ribozym med en termodynamisk stabil lökke
KR920019342A (ko) 골질환 치료제
ATE343969T1 (de) Beschichtete medizinische geräte
NO20034684L (no) Mikroprojeksjonsanordning med belegg inneholdende et fordelaktig middel
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
DK1137762T3 (da) Behandling af Pompes sygdom
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
DK1295600T3 (da) Lægemiddel baseret på gestagener til dermal anvendelse indeholdende ascorbinsyre og/eller salte deraf
PT974350E (pt) Preparacao contendo tranilast para aplicacao externa e metedo para a sua producao
ATE188119T1 (de) Heilmittel für wunden und hämorrhoiden
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DK261490D0 (da) New pharmaceutical compound
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
AU3401093A (en) Therapeutic agent for threatened abortion
AU2251302A (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων
CY1106235T1 (el) Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
ES2053834T3 (es) Un metodo para la preparacion de una sustancia terapeutica.
DE3877499D1 (de) 2,6-diamino-3-phenyl-azo-pyridin enthaltendes tier- und humanarzneimittel mit antiviraler und antitumoraler aktivitaet.
FR2764506B1 (fr) Composition therapeutique ou hygienique a liberation controlee et prolongee de principe(s) actif(s), notamment a usage ophtalmique
UA12937A (uk) Засіб для локальhого лікуваhhя гhійhо-запальhих раh та опіків, іhфіковаhих стафілококом
IT211928Z2 (it) Cappellotto di cop}rtura degli aghi, particolarmente per siringhe monouso.